Metsera (NASDAQ:MTSR – Get Free Report) posted its earnings results on Wednesday. The company reported ($3.52) EPS for the quarter, Zacks reports.
Metsera Price Performance
Metsera stock traded down $0.70 during trading on Wednesday, reaching $28.46. The company had a trading volume of 31,153 shares, compared to its average volume of 664,188. Metsera has a 1-year low of $23.08 and a 1-year high of $32.81.
Analysts Set New Price Targets
Several research firms have commented on MTSR. Guggenheim began coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Evercore ISI initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “outperform” rating on the stock. Bank of America assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating on the stock.
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- What is a penny stock? A comprehensive guide
- Palantir Setting Up to Be a Big Winner With New Defense Spending
- What does consumer price index measure?
- Advanced Micro Devices Can Double in Price: Here’s Why
- How to Invest in Insurance Companies: A Guide
- How Disney’s Experiences Segment Can Restore the House of Mouse
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.